Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

European Respiratory Journal

Volumn 40, Issue 4, 2012, Pages 1014-1023

  Hurley, Matthew N ^a   Cámara, Miguel ^a   Smyth, Alan R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antibiotic resistance; Antibiotic treatment; Cystic fibrosis and chronic infections; Pseudomonas

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; DEFEROXAMINE; EFFLUX PUMP INHIBITOR; ENDOTOXIN A TOXOID; GALLIUM; GARLIC EXTRACT; IRON CHELATING AGENT; LECTIN INHIBITOR; PROTEIN INHIBITOR; TOBRAMYCIN; TOXOID; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL VIRULENCE; BACTERIOPHAGE; DISEASE ASSOCIATION; DRUG ACTIVITY; EFFUSION; ENDOLYSIN; GENETICS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; INNATE IMMUNITY; LUNG FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PUMP; QUORUM SENSING; REVIEW;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUORUM SENSING;

EID: 84867115760     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00042012     Document Type: Review

References (107)

1. European Commission and Directorate General for Health and Consumers. Communication from the Commission to the European Parliament and the Council Action plan against the rising threats from Antimicrobial Resistance. 2011 Contract No. COM (2011) 748.
2. European Centre of Disease Prevention and Control. Antimicrobial resistance surveillance in Europe. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, ECDC, 2011.
3. Garcia-Vidal C, Almagro P, Romaní V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J 2009; 34: 1072-1078.
4. Sadikot RT, Blackwell TS, Christman JW, et al. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171: 1209-1223. (Pubitemid 40740727)
5. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100. (Pubitemid 34809519)
6. Mouton JW, den Hollander JG, Horrevorts AM. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993; 31: 919-926. (Pubitemid 23218154)
7. Langton-Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009; 4: CD004197.
8. Talbot G, Bradley J, Edwards JJ, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-668. (Pubitemid 43271379)
9. Hurley MN, Forrester DL, Smyth AR. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cochrane Database Syst Rev 2010; 10: CD008037.
10. Macdonald D, Cuthbertson L, Doherty C, et al. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified? J Antimicrob Chemother 2010; 65: 2373-2375.
11. Tramper-Stranders GA, van der Ent CK, Molin S, et al. Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates. Clinical Microbiol Infect 2012; 18: 567-574.
12. Drenkard E, Ausubel F. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416: 740-743. (Pubitemid 34429150)
13. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293: 581-588. (Pubitemid 40171240)
14. Fothergill JL, Mowat E, Ledson MJ, et al. Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. J Med Microbiol 2010; 59: 472-481.
15. Oliver A, Canton R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-1253. (Pubitemid 30367204)
16. Walters MC 3rd, Roe F, Bugnicourt A, et al. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003; 47: 317-323. (Pubitemid 36070381)
17. Keren I, Kaldalu N, Spoering A, et al. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 2004; 230: 13-18. (Pubitemid 38091733)
18. Zar H, Saiman L, Quittell L, et al. Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr 1995; 126: 230-233.
19. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 1997; 94: 12088-12093. (Pubitemid 27467847)
20. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 2011; 3: CD001021.
21. Sawicki GS, Signorovitch JE, Zhang J, et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012; 47: 44-52.
22. Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65: 286-291.
23. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011; 10: 54-61.
24. Konstan MW, Flume PA, Brockhous F, et al. Safety and efficacy of tobramycin inhalation powder (TIPTM) in treating cystic fibrosis patients infected with Pseudomonas aeruginosa (Pa). J Cyst Fibros 2010; 9: Suppl. 1, S22.
25. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921-928.
26. Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009; 8: 295-315.
27. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 183: 1510-1516.
28. Srinivas N, Jetter P, Ueberbacher BJ, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 2010; 327: 1010-1013.
29. Hentzer M, Teitzel G, Balzer G, et al. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 2001; 183: 5395-5401. (Pubitemid 32802613)
30. Alkawash MA, Soothill JS, Schiller NL. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS 2006; 114: 131-138. (Pubitemid 43356924)
31. Riedel K, Hentzer M, Geisenberger O, et al. N-Acylhomoserinelactone- mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology 2001; 147: 3249-3262. (Pubitemid 33150331)
32. Telford G, Wheeler D, Williams P, et al. The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-Lhomoserine lactone has immunomodulatory activity. Infect Immun 1998; 66: 36-42.
33. Woodford N, Wareham DW, on behalf of the UK Antibacterial Antisense Study Group. Tackling antibiotic resistance: a dose of common antisense? J Antimicrob Chemother 2009; 63: 225-229.
34. Barken K, Pamp S, Yang L, et al. Roles of type IV pili, flagellum-mediated motility and extracellular DNA in the formation of mature multicellular structures in Pseudomonas aeruginosa biofilms. Environ Microbiol 2008; 10: 2331-2343.
35. van Schaik EJ, Giltner CL, Audette GF, et al. DNA Binding: a novel function of Pseudomonas aeruginosa type IV pili. J Bacteriol 2005; 187: 1455-1464. (Pubitemid 40299469)
36. Alibert-Franco S, Pradines B, Mahamoud A, et al. Efflux mechanism, an attractive target to combat multidrug resistant Plasmodium falciparum and Pseudomonas aeruginosa. Curr Med Chem 2009; 16: 301-317.
37. Coban A, Ekinci B, Durupinar B. A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates. Chemotherapy 2004; 50: 22-26. (Pubitemid 38490195)
38. Tielker D, Hacker S, Loris R, et al. Pseudomonas aeruginosa lectin LecB is located in the outer membrane and is involved in biofilm formation. Microbiology 2005; 151: 1313-1323. (Pubitemid 40711779)
39. Adam E, Mitchell B, Schumacher D, et al. Pseudomonas aeruginosa II lectin stops human ciliary beating: therapeutic implications of fucose. Am J Respir Crit Care Med 1997; 155: 2102-2104. (Pubitemid 27256143)
40. Doring G, Meisner C, Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci USA 2007; 104: 11020-11025. (Pubitemid 47175219)
41. Jensen P, Bjarnsholt T, Phipps R, et al. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 2007; 153: 1329-1338. (Pubitemid 46779989)
42. Diggle S, Matthijs S, Wright V, et al. The Pseudomonas aeruginosa 4-quinolone signal molecules HHQ and PQS play multifunctional roles in quorum sensing and iron entrapment. Chem Biol 2007; 14: 87-96. (Pubitemid 46138049)
43. Halwani M, Yebio B, Suntres ZE, et al. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J Antimicrob Chemother 2008; 62: 1291-1297.
44. Manafi A, Kohanteb J, Mehrabani D, et al. Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model. BMC Microbiol 2009; 9: 23.
45. Milla CE, Accorso FJ, Chmiel J, et al. Modulating Pseudomonas aeruginosa chronic inflammation with the anti-PcrV antibody KB001: results of a pilot clinical and pharmacodynamic study in subjects with cystic fibrosis. Am J Respir Crit Care Med 2010; 181: A1845.
46. Gardiner SM, Chhabra SR, Harty C, et al. Haemodynamic effects of the bacterial quorum sensing signal molecule, N-(3-oxododecanoyl)-L-homoserine lactone, in conscious, normal and endotoxaemic rats. Br J Pharmacol 2001; 133: 1047-1054. (Pubitemid 32762415)
47. Fuqua C, Winans SC, Greenberg EP. Census and consensus in bacterial ecosystems the LuxR-LuxI family of quorumsensing transcriptional regulators. Annu Rev Microbiol 1996; 50: 727-751. (Pubitemid 26337480)
48. Williams P, Winzer K, Chan WC, et al. Look who's talking: communication and quorum sensing in the bacterial world. Philos Trans R Soc Lond B Biol Sci 2007; 362: 1119-1134. (Pubitemid 47075145)
49. Diggle SP, Cornelis P, Williams P, et al. 4-quinolone signalling in Pseudomonas aeruginosa: old molecules, new perspectives. Int J Med Microbiol 2006; 296: 83-91. (Pubitemid 43375990)
50. Pearson J, Van Delden C, Iglewski B. Active efflux and diffusion are involved in transport of Pseudomonas aeruginosa cell-to-cell signals. J Bacteriol 1999; 181: 1203-1210. (Pubitemid 29119559)
51. Mashburn LM, Whiteley M. Membrane vesicles traffic signals and facilitate group activities in a prokaryote. Nature 2005; 437: 422-425. (Pubitemid 41613505)
52. Williams P, Cámara M. Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules. Curr Opin Microbiol 2009; 12: 182-191.
53. Bjarnsholt T, Jensen P, Burmølle M, et al. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 2005; 151: 373-383. (Pubitemid 40277742)
54. Davies D, Parsek M, Pearson J, et al. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998; 280: 295-298. (Pubitemid 28178075)
55. Diggle S, Winzer K, Chhabra S, et al. The Pseudomonas aeruginosa quinolone signal molecule overcomes the cell density-dependency of the quorum sensing hierarchy, regulates rhl-dependent genes at the onset of stationary phase and can be produced in the absence of LasR. Mol Microbiol 2003; 50: 29-43. (Pubitemid 37222784)
56. Christensen L, Moser C, Jensen P, et al. Impact of Pseudomonas aeruginosa quorum sensing on biofilm persistence in an in vivo intraperitoneal foreign-body infection model. Microbiology 2007; 153: 2312-2320. (Pubitemid 47074084)
57. Dong Y, Wang L, Zhang L. Quorum-quenching microbial infections: mechanisms and implications. Philos Trans R Soc Lond B Biol Sci 2007; 362: 1201-1211. (Pubitemid 47075151)
58. Chambers CE, Visser MB, Schwab U, et al. Identification of N-acylhomoserine lactones in mucopurulent respiratory secretions from cystic fibrosis patients. FEMS Microbiol Lett 2005; 244: 297-304. (Pubitemid 40342842)
59. Middleton B, Rodgers H, Cámara M, et al. Direct detection of N-acylhomoserine lactones in cystic fibrosis sputum. FEMS Microbiol Lett 2002; 207: 1-7. (Pubitemid 34214797)
60. Fulghesu L, Giallorenzo C, Savoia D. Evaluation of different compounds as quorum sensing inhibitors in Pseudomonas aeruginosa. J Chemother 2007; 19: 388-391.
61. Smith K, Bu Y, Suga H. Library screening for synthetic agonists and antagonists of a Pseudomonas aeruginosa autoinducer. Chem Biol 2003; 10: 563-571. (Pubitemid 36774641)
62. Bjarnsholt T, Jensen P, Rasmussen T, et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology 2005; 151: 3873-3880. (Pubitemid 41829968)
63. Smyth AR, Cifelli PM, Ortori CA, et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis - a pilot randomized controlled trial. Pediatr Pulmonol 2010; 45: 356-362.
64. Skindersoe M, Alhede M, Phipps R, et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 3648-3663.
65. Hoffmann N, Lee B, Hentzer M, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr-/- mice. Antimicrob Agents Chemother 2007; 51: 3677-3687. (Pubitemid 47519359)
66. Diggle S, Stacey R, Dodd C, et al. The galactophilic lectin, LecA, contributes to biofilm development in Pseudomonas aeruginosa. Environ Microbiol 2006; 8: 1095-1104. (Pubitemid 43901776)
67. Kadam RU, Bergmann M, Hurley M, et al. A glycopeptide dendrimer inhibitor of the galactose-specific lectin LecA and of Pseudomonas aeruginosa biofilms. Angew Chem Int Ed Engl 2011; 50: 10631-10635.
68. Johansson E, Crusz S, Kolomiets E, et al. Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB. Chem Biol 2008; 15: 1249-1257. (Pubitemid 352841467)
69. Hauber H, Schulz M, Pforte A, et al. Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. Int J Med Sci 2008; 5: 371-376.
70. Kolomiets E, Swiderska MA, Kadam RU, et al. Glycopeptide dendrimers with high affinity for the fucose-binding lectin LecB from Pseudomonas aeruginosa. Chem Med Chem 2009; 4: 562-569.
71. Mateos F, Brock JH, Pérez-Arellano JL. Iron metabolism in the lower respiratory tract. Thorax 1998; 53: 594-600. (Pubitemid 28335522)
72. Reid DW, Carroll V, O'May C, et al. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis. Eur Respir J 2007; 30: 286-292. (Pubitemid 47194181)
73. Martin LW, Reid DW, Sharples KJ, et al. Pseudomonas siderophores in the sputum of patients with cystic fibrosis. BioMetals 2011; 24: 1059-1067.
74. Meyer JM, Neely A, Stintzi A, et al. Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Infect Immun 1996; 64: 518-523. (Pubitemid 26032823)
75. Singh PK, Parsek MR, Greenberg EP, et al. A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417: 552-555. (Pubitemid 34595922)
76. Xiao R, Kisaalita WS. Iron acquisition from transferrin and lactoferrin by Pseudomonas aeruginosa pyoverdin. Microbiology 1997; 143: 2509-2515. (Pubitemid 27356786)
77. Britigan BE, Hayek MB, Doebbeling BN, et al. Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis. Infect Immun 1993; 61: 5049-5055. (Pubitemid 23353879)
78. Lamont IL, Konings AF, Reid DW. Iron acquisition by Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. BioMetals 2009; 22: 53-60.
79. Moreau-Marquis S, O'Toole GA, Stanton BA. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol 2009; 41: 305-313.
80. Piddock L. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol 2006; 4: 629-636. (Pubitemid 44317025)
81. Zhang L, Mah T. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J Bacteriol 2008; 190: 4447-4452. (Pubitemid 351898960)
82. Hocquet D, Roussel-Delvallez M, Cavallo J-D, et al. MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin. Antimicrob Agents Chemother 2007; 51: 1582-1583. (Pubitemid 46586860)
83. Sanchez P, Linares JF, Ruiz-Diez B, et al. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J Antimicrob Chemother 2002; 50: 657-664. (Pubitemid 35331682)
84. Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45: 105-116. (Pubitemid 32039101)
85. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006; 19: 382-402.
86. Renau TE, Léger R, Yen R, et al. Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg Med Chem Lett 2002; 12: 763-766. (Pubitemid 34164613)
87. Tan X-X,Actor JK, Chen Y. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection. Antimicrob Agents Chemother 2005; 49: 3203-3207. (Pubitemid 41060562)
88. Wesolowski D, Tae HS, Gandotra N, et al. Basic peptidemorpholino oligomer conjugate that is very effective in killing bacteria by gene-specific and nonspecific modes. Proc Natl Acad Sci USA 2011; 108: 16582-16587.
89. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45: 649-659. (Pubitemid 32182003)
90. Donlan RM. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol 2009; 17: 66-72.
91. Hagens S, Habel A, von Ahsen U, et al. Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 2004; 48: 3817-3822. (Pubitemid 39304609)
92. Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. Med Mal Infect 2008; 38: 426-430.
93. Wright A, Hawkins C, Änggard E, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa: a preliminary report of efficacy. Clin Otolaryngol 2009; 34: 349-357.
94. Wolcott R. A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers (NCT00663091). ClinicalTrials.gov Date last accessed: November 30, 201. Date last updated: September 6, 2011.
95. Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol Lett 2007; 29: 995-1003. (Pubitemid 46800624)
96. Fancello L, Desnues C, Raoult D, et al. Bacteriophages and diffusion of genes encoding antimicrobial resistance in cystic fibrosis sputum microbiota. J Antimicrob Chemother 2011; 66: 2448-2454.
97. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294: 2170-2172. (Pubitemid 33150674)
98. Borysowski J, Weber-Dabrowska B, Gorski A. Bacteriophage endolysins as a novel class of antibacterial agents. Expe Biol Med 2006; 231: 366-377.
99. Briers Y, Walmagh M, Lavigne R. Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J Appl Microbiol 2011; 110: 778-785.
100. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2008; 4: CD001399.
101. Nilsson E, Larsson A, Olesen HV, et al. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol 2008; 43: 892-899.
102. Kollberg HNE, Jobannesson M, Wejker PE, et al. Anti-Pseudomonas IgY is now licensed for prophylaxis and treatment of CF patients in Sweden. J Cyst Fibros 2005; 4: Suppl. 1, S28.
103. Lu Q, Rouby J-J, Laterre P-F, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother 2011; 66: 1110-1116.
104. Baer M, Sawa T, Flynn P, et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 2009; 77: 1083-1090.
105. Moskwa P, Lorentzen D, Excoffon KJ, et al. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 174-183. (Pubitemid 46115089)
106. Georgi E, Le Guellec S, Vecellio L, et al. Feasibility study of OSCN- and lactoferrin (Meveol) nebulization for cystic fibrosis patients. J Cystic Fibros 2011; 10: Suppl. 1, S18.
107. Mahamoud A, Chevalier J, Alibert-Franco S, et al. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemother 2007; 59: 1223-1229. (Pubitemid 47073340)